Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout
Due to reliance on antimalarials for clinical case management, drug resistance is a recurrent challenge for malaria control and elimination that requires relentless discovery and development of novel medicines with new modes of action.1 Since the widespread use of chloroquine in the 1950s, resistanc...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2023-09, Vol.23 (9), p.990-992 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 992 |
|---|---|
| container_issue | 9 |
| container_start_page | 990 |
| container_title | The Lancet infectious diseases |
| container_volume | 23 |
| creator | Chen, Ingrid Ishengoma, Deus S |
| description | Due to reliance on antimalarials for clinical case management, drug resistance is a recurrent challenge for malaria control and elimination that requires relentless discovery and development of novel medicines with new modes of action.1 Since the widespread use of chloroquine in the 1950s, resistance has compromised the efficacy of all major classes of antimalarial drugs that are widely used to treat Plasmodium falciparum. A phase 2 safety and efficacy study in children aged 6 months and older is underway (NCT04546633), and a phase 3 trial will commence this year.7 Regulatory discussions have been initiated with various agencies, including the US Food and Drug Administration and Marketing Authorisation for Global Health Products in Switzerland, which involves WHO and regulators from disease endemic countries (Wells T, Medicines for Malaria Venture, personal communication). For regulatory approvals, WHO prequalification will be essential to enable drug availability in endemic countries using major funders, including UNITAID and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.9 For manufacturing, ample production with backup facilities in case of supply chain disruptions and drug stock-outs will be necessary. |
| doi_str_mv | 10.1016/S1473-3099(23)00231-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2827253412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309923002311</els_id><sourcerecordid>2827253412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-512e6323b1e2468fe9159f3d7f89d15e6b90b9834e5173ab4753601871efe5243</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhS0EoqXwCCBLbMoi4PFPnLCpUAUFqRILYG058Vhy5djBTirx9vjeW1iwYeXx-Dsz1jmEvAT2Fhj0776B1KITbBwvuXjDGBfQwSNy3tqyk1Lpx8f6hJyRZ7XeMQYamHxKzoQWXA_Azom_scmu0c7BIV3jXmncF_Q2bSUkpDXH4KgLdcVSQ07U57Ls0W6tfk_nnGrTleO1Ht6ow3uMeV0wbdQmR0uOMe_bc_LE21jxxcN5QX58-vj9-nN3-_Xmy_WH224WErZOAcdecDEBctkPHkdQoxdO-2F0oLCfRjaNg5CoQAs7Sa1Ez2DQgB4Vl-KCXJ7mriX_3LFuZgl1xhhtwrxXwweuuWq7eENf_4Pe5b2k9rtGqZ4PsteiUepEzSXXWtCbtYTFll8GmDkEYY5BmIPLhgtzDMJA0716mL5PC7q_qj_ON-DqBGCz4z5gMXUOmGZ0oeC8GZfDf1b8BoHUmBs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2856284673</pqid></control><display><type>article</type><title>Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Chen, Ingrid ; Ishengoma, Deus S</creator><creatorcontrib>Chen, Ingrid ; Ishengoma, Deus S</creatorcontrib><description>Due to reliance on antimalarials for clinical case management, drug resistance is a recurrent challenge for malaria control and elimination that requires relentless discovery and development of novel medicines with new modes of action.1 Since the widespread use of chloroquine in the 1950s, resistance has compromised the efficacy of all major classes of antimalarial drugs that are widely used to treat Plasmodium falciparum. A phase 2 safety and efficacy study in children aged 6 months and older is underway (NCT04546633), and a phase 3 trial will commence this year.7 Regulatory discussions have been initiated with various agencies, including the US Food and Drug Administration and Marketing Authorisation for Global Health Products in Switzerland, which involves WHO and regulators from disease endemic countries (Wells T, Medicines for Malaria Venture, personal communication). For regulatory approvals, WHO prequalification will be essential to enable drug availability in endemic countries using major funders, including UNITAID and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.9 For manufacturing, ample production with backup facilities in case of supply chain disruptions and drug stock-outs will be necessary.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(23)00231-1</identifier><identifier>PMID: 37327810</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antimalarial agents ; Antiparasitic agents ; Chloroquine ; Drug dosages ; Drug resistance ; Effectiveness ; FDA approval ; Global health ; Infectious diseases ; Malaria ; Manufacturing ; Personal communication ; Public health ; Supply chains ; Vector-borne diseases</subject><ispartof>The Lancet infectious diseases, 2023-09, Vol.23 (9), p.990-992</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c341t-512e6323b1e2468fe9159f3d7f89d15e6b90b9834e5173ab4753601871efe5243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2856284673?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37327810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Ingrid</creatorcontrib><creatorcontrib>Ishengoma, Deus S</creatorcontrib><title>Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Due to reliance on antimalarials for clinical case management, drug resistance is a recurrent challenge for malaria control and elimination that requires relentless discovery and development of novel medicines with new modes of action.1 Since the widespread use of chloroquine in the 1950s, resistance has compromised the efficacy of all major classes of antimalarial drugs that are widely used to treat Plasmodium falciparum. A phase 2 safety and efficacy study in children aged 6 months and older is underway (NCT04546633), and a phase 3 trial will commence this year.7 Regulatory discussions have been initiated with various agencies, including the US Food and Drug Administration and Marketing Authorisation for Global Health Products in Switzerland, which involves WHO and regulators from disease endemic countries (Wells T, Medicines for Malaria Venture, personal communication). For regulatory approvals, WHO prequalification will be essential to enable drug availability in endemic countries using major funders, including UNITAID and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.9 For manufacturing, ample production with backup facilities in case of supply chain disruptions and drug stock-outs will be necessary.</description><subject>Antimalarial agents</subject><subject>Antiparasitic agents</subject><subject>Chloroquine</subject><subject>Drug dosages</subject><subject>Drug resistance</subject><subject>Effectiveness</subject><subject>FDA approval</subject><subject>Global health</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Manufacturing</subject><subject>Personal communication</subject><subject>Public health</subject><subject>Supply chains</subject><subject>Vector-borne diseases</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1u1TAQhS0EoqXwCCBLbMoi4PFPnLCpUAUFqRILYG058Vhy5djBTirx9vjeW1iwYeXx-Dsz1jmEvAT2Fhj0776B1KITbBwvuXjDGBfQwSNy3tqyk1Lpx8f6hJyRZ7XeMQYamHxKzoQWXA_Azom_scmu0c7BIV3jXmncF_Q2bSUkpDXH4KgLdcVSQ07U57Ls0W6tfk_nnGrTleO1Ht6ow3uMeV0wbdQmR0uOMe_bc_LE21jxxcN5QX58-vj9-nN3-_Xmy_WH224WErZOAcdecDEBctkPHkdQoxdO-2F0oLCfRjaNg5CoQAs7Sa1Ez2DQgB4Vl-KCXJ7mriX_3LFuZgl1xhhtwrxXwweuuWq7eENf_4Pe5b2k9rtGqZ4PsteiUepEzSXXWtCbtYTFll8GmDkEYY5BmIPLhgtzDMJA0716mL5PC7q_qj_ON-DqBGCz4z5gMXUOmGZ0oeC8GZfDf1b8BoHUmBs</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Chen, Ingrid</creator><creator>Ishengoma, Deus S</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20230901</creationdate><title>Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout</title><author>Chen, Ingrid ; Ishengoma, Deus S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-512e6323b1e2468fe9159f3d7f89d15e6b90b9834e5173ab4753601871efe5243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antimalarial agents</topic><topic>Antiparasitic agents</topic><topic>Chloroquine</topic><topic>Drug dosages</topic><topic>Drug resistance</topic><topic>Effectiveness</topic><topic>FDA approval</topic><topic>Global health</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Manufacturing</topic><topic>Personal communication</topic><topic>Public health</topic><topic>Supply chains</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Ingrid</creatorcontrib><creatorcontrib>Ishengoma, Deus S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Ingrid</au><au>Ishengoma, Deus S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>23</volume><issue>9</issue><spage>990</spage><epage>992</epage><pages>990-992</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Due to reliance on antimalarials for clinical case management, drug resistance is a recurrent challenge for malaria control and elimination that requires relentless discovery and development of novel medicines with new modes of action.1 Since the widespread use of chloroquine in the 1950s, resistance has compromised the efficacy of all major classes of antimalarial drugs that are widely used to treat Plasmodium falciparum. A phase 2 safety and efficacy study in children aged 6 months and older is underway (NCT04546633), and a phase 3 trial will commence this year.7 Regulatory discussions have been initiated with various agencies, including the US Food and Drug Administration and Marketing Authorisation for Global Health Products in Switzerland, which involves WHO and regulators from disease endemic countries (Wells T, Medicines for Malaria Venture, personal communication). For regulatory approvals, WHO prequalification will be essential to enable drug availability in endemic countries using major funders, including UNITAID and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.9 For manufacturing, ample production with backup facilities in case of supply chain disruptions and drug stock-outs will be necessary.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>37327810</pmid><doi>10.1016/S1473-3099(23)00231-1</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2023-09, Vol.23 (9), p.990-992 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2827253412 |
| source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Antimalarial agents Antiparasitic agents Chloroquine Drug dosages Drug resistance Effectiveness FDA approval Global health Infectious diseases Malaria Manufacturing Personal communication Public health Supply chains Vector-borne diseases |
| title | Ganaplacide plus lumefantrine solid dispersion formulation: considerations for development and rollout |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A51%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ganaplacide%20plus%20lumefantrine%20solid%20dispersion%20formulation:%20considerations%20for%20development%20and%20rollout&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Chen,%20Ingrid&rft.date=2023-09-01&rft.volume=23&rft.issue=9&rft.spage=990&rft.epage=992&rft.pages=990-992&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(23)00231-1&rft_dat=%3Cproquest_cross%3E2827253412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2856284673&rft_id=info:pmid/37327810&rft_els_id=S1473309923002311&rfr_iscdi=true |